ALEXIS Biochemicals: Pseudolaric acid B

ALX-350-108

Revised 08-Apr-08

Pseudolaric acid B
SYNONYMS	Pseudolarix acid B PLAB PAB
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Other Natural Products - DNA Regulation/Transcription

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-350-108-MC01		0.1 mg	35.00 USD
ALX-350-108-M001		1 mg	95.00 USD

Product Specification

FORMULA:	C₂₃H₂₈O₈
MW:	432.5
CAS NUMBER:	82508-31-4
SOURCE/HOST:	Isolated from Pseudolarix kaempferi.
PURITY:	≥95%
APPEARANCE:	Off-white to light brown solid.
SOLUBILITY:	Soluble in DMSO, 100% ethanol or chloroform.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	+4°C
HANDLING:	Protect from moisture.

Product Description

Activates PPARα and the phospholipase C (PLC) signalling pathway. Stimulates peroxisomal fatty acyl-CoA oxidase activity. These effects can be blocked by staurosporine (Prod. No. ALX-380-014). Exhibits significant cytotoxic activities against numerous tumor cell lines. Binds tubulin. Inhibits angiogenesis. Reduces HIF-1α protein levels. Induces apoptosis. Antifungal.

Product Specific Literature References

Pseudolaric Acids from Pseudolarix kaempferi: B.N. Zhou, et al.; Planta Med. 47, 35 (1983) Abstract
The cytotoxic principles of Pseudolarix kaempferi: pseudolaric acid-A and -B and related derivatives: D.J. Pan, et al.; Planta Med. 56, 383 (1990) Abstract
Antifungal evaluation of pseudolaric acid B, a major constituent of Pseudolarix kaempferi: E. Li, et al.; J. Nat. Prod. 58, 57 (1995) Abstract
Pseudolaric acid analogs as a new class of peroxisome proliferator-activated receptor agonists: M.S. Jardat, et al.; Planta Med. 68, 667 (2002) Abstract
Five new diterpenoids from Pseudolarix kaempferi: S.P. Yang, et al.; J. Nat. Prod. 65, 1041 (2002) Abstract
Antifungal diterpenoids of Pseudolarix kaempferi, and their structure-activity relationship study: S.P. Yang, et al.; Bioorg. Med. Chem. 11, 4577 (2003) Abstract
Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect: W.F. Tan, et al.; Eur. J. Pharmacol. 499, 219 (2004) Abstract
Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation: M.H. Li, et al.; Clin. Cancer Res. 10, 8266 (2004) Abstract
Pseudolaric acid B induces apoptosis through p53 and Bax/Bcl-2 pathways in human melanoma A375-S2 cells: X.F. Gong, et al.; Arch. Pharm. Res. 28, 68 (2005) Abstract
Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo: V.K. Wong, et al.; Clin. Cancer Res. 11, 6002 (2005) Abstract
Effect of pseudolaric acid B on gastric cancer cells: inhibition of proliferation and induction of apoptosis: K.S. Li, et al.; World J. Gastroenterol. 11, 7555 (2005) Abstract; Full Text
Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin: Y.G. Tong, et al.; Mol. Pharmacol. 69, 1226 (2006) Abstract
Involvement of JNK-initiated p53 accumulation and phosphorylation of p53 in pseudolaric acid B induced cell death: X. Gong, et al.; Exp. Mol. Med. 38, 428 (2006) Abstract; Full Text
Studies on anti-tumour activities of pseudolaric acid-B (PLAB) and its mechanism of action: B. Liu, et al.; J. Asian Nat. Prod. Res. 8, 241 (2006) Abstract
Herbal diterpenoids induce growth arrest and apoptosis in colon cancer cells with increased expression of the nonsteroidal anti-inflammatory drug-activated gene: J.K. Ko, et al.; Eur. J. Pharmacol. 559, 1 (2007) Abstract
Structural modification of an angiogenesis inhibitor discovered from traditional chinese medicine and a structure-activity relationship study: S.P. Yang, et al.; J. Med. Chem. 51, 77 (2008) Abstract